Type 2 Diabetes Clinical Trial
Official title:
Beneficial Effects of Quinoa (Chenopodium Quinoa Willd) in the Prevention of Type 2 Diabetes Mellitus
| NCT number | NCT04529317 |
| Other study ID # | Quinoa |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | May 2016 |
| Est. completion date | September 2016 |
| Verified date | August 2020 |
| Source | Institut d'Investigacions Biomèdiques August Pi i Sunyer |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Quinoa is a pseudo-cereal and has potential health benefits and exceptional nutritional
value. It is a food rich in proteins of high biological value, in unsaturated fats and fiber,
it is also a grain low in carbohydrates and with a low glycemic index. Concretely, quinoa
could produce a benefit on postprandial glycemia that would result in lower type 2 diabetes
(T2D) incidence.
A cross-over design pilot clinical study with a nutritional intervention for 8 weeks were
performed: 4 weeks on a regular diet (RD) and 4 weeks on a quinoa diet (QD). Nine subjects
aged ≥65 years with prediabetes were monitored during the first 4 weeks of RD with daily
dietary records and FreeStyle Libre®. Subsequently, participants started the DQ where quinoa
and 100% quinoa-based products replaced foods rich in complex carbohydrates that they
regularly consumed by the first 4 weeks of DR.
The glycemic measurements recorded by the sensors were considered as functions of time and
the effects of nutrients consumed at the intended time period were analyzed by means of
function on scalar regression (fosr) model.
| Status | Completed |
| Enrollment | 9 |
| Est. completion date | September 2016 |
| Est. primary completion date | September 2016 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 65 Years and older |
| Eligibility |
Inclusion Criteria: - Glucose levels between 100 and 125 mg/dL and without a previous diagnosis of diabetes Exclusion Criteria: - Do not consume a diet with daily presence of grains or cereals derivatives, tubers or/and legumes, or they presented any other health problem that the research staff considered contraindicated: Treatment with oral antidiabetic drugs Chronic treatment with oral steroids and / or AINES Treatment with oral antidiabetic agents and / or insulin Treatment with immunosuppressive drugs Diagnosis of active neoplasm Diagnosis of HIV or AIDS Abnormal liver profile (> 6 times normal values) Diagnosis of Acute Psychiatric Sdr Presence of serious acute concomitant disease, which it requires more than 7 days of recovery. Major cardiovascular event (stroke, myocardial infarction) in the month prior to randomization. Any other condition that the investigator considers to be inoperative so that the subject conducts the study. |
| Country | Name | City | State |
|---|---|---|---|
| Spain | Diana A. Díaz Rizzolo | Barcelona |
| Lead Sponsor | Collaborator |
|---|---|
| Institut d'Investigacions Biomèdiques August Pi i Sunyer |
Spain,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Hs-CRP (high-sensitivity C-reactive protein) in mg/L | Fasting blood samples were collected by a nurse and they were analyzed by the Biomedical Diagnosis Centre (CDB) in Hospital Clinic de Barcelona. | Data obtained after 28 days quinoa diet compared to data obtained after 28 days regular diet | |
| Other | HDL (high-density lipoprotein) in mg/dL | Fasting blood samples were collected by a nurse and they were analyzed by the Biomedical Diagnosis Centre (CDB) in Hospital Clinic de Barcelona. | Data obtained after 28 days quinoa diet compared to data obtained after 28 days regular diet | |
| Other | LDL (low-density lipoprotein) in mg/dL | Fasting blood samples were collected by a nurse and they were analyzed by the Biomedical Diagnosis Centre (CDB) in Hospital Clinic de Barcelona. | Data obtained after 28 days quinoa diet compared to data obtained after 28 days regular diet | |
| Other | Total cholesterol in mg/dL | Fasting blood samples were collected by a nurse and they were analyzed by the Biomedical Diagnosis Centre (CDB) in Hospital Clinic de Barcelona. | Data obtained after 28 days quinoa diet compared to data obtained after 28 days regular diet | |
| Other | Triglycerides in mg/dL | Fasting blood samples were collected by a nurse and they were analyzed by the Biomedical Diagnosis Centre (CDB) in Hospital Clinic de Barcelona. | Data obtained after 28 days quinoa diet compared to data obtained after 28 days regular diet | |
| Other | Serum albumin in g/dL | Fasting blood samples were collected by a nurse and they were analyzed by the Biomedical Diagnosis Centre (CDB) in Hospital Clinic de Barcelona. | Data obtained after 28 days quinoa diet compared to data obtained after 28 days regular diet | |
| Primary | Blood glucose fluctuations | Glucose fluctuations were measured by FreeStyle Libre® Flash Glucose Monitoring System (Abbott Laboratories) which measures interstitial fluid glucose concentrations. The sensor was applied by researchers on to the back of the upper arm of subjects using the applicator and participants were trained to obtain electronically all the glucose records concentrations every 15 minutes so they had to scan at least once every eight hours. The glucose level monitoring sensor takes measurements at discrete time points for each patient Therefore, firstly the glucose curves have been linearly interpolated and has been considered as a function of time in minutes over interval. Then, a functional model analyses were constructed as described in "study protocol and statistical analyses" document attached. | Comparing data obtained during 2 hours per day along 14 days both during regular diet and quinoa diet | |
| Secondary | Weight in kilograms | Subjects were weighed without clothing and shoes. | Data obtained after 28 days quinoa diet compared to data obtained after 28 days regular diet | |
| Secondary | Height in meters | Subjects were measured without clothing and shoes. | Data obtained after 28 days quinoa diet compared to data obtained after 28 days regular diet | |
| Secondary | Body mass index (BMI) | BMI was calculated as weight (kg)/height (m)² | Data obtained after 28 days quinoa diet compared to data obtained after 28 days regular diet | |
| Secondary | Circumferences in cm | waist circumference was measured at the midpoint between the last rib and the iliac crest and hip circumference at the widest point of the gluteus | Data obtained after 28 days quinoa diet compared to data obtained after 28 days regular diet | |
| Secondary | Blood pressure | Blood pressure was taken after individuals sat quietly for 5 min in a clinical examination room. The mean of three different measurements, obtained every 3 min using an OMRON M6 AC sphygmomanometer, was recorded. | Data obtained after 28 days quinoa diet compared to data obtained after 28 days regular diet | |
| Secondary | Insulin levels (mU/L) | Fasting blood samples were collected by a nurse and they were analyzed by the Biomedical Diagnosis Centre (CDB) in Hospital Clinic de Barcelona. | Data obtained after 28 days quinoa diet compared to data obtained after 28 days regular diet | |
| Secondary | Glucose homeostasis (mg/dl) | Fasting blood samples were collected by a nurse and they were analyzed by the Biomedical Diagnosis Centre (CDB) in Hospital Clinic de Barcelona. | Data obtained after 28 days quinoa diet compared to data obtained after 28 days regular diet | |
| Secondary | Glycated hemoglobin HbA1c (%) | Fasting blood samples were collected by a nurse and they were analyzed by the Biomedical Diagnosis Centre (CDB) in Hospital Clinic de Barcelona. | Data obtained after 28 days quinoa diet compared to data obtained after 28 days regular diet | |
| Secondary | Nutrient intake recorded | Nutritional patterns were measured using a 14-days dietary record revised corrected by a nutritionist and analyzed by the DIAL nutritional calculation program. | Data obtained during 28 days quinoa diet compared to data obtained during 28 days regular diet |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
| Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
| Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
| Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
| Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
| Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
| Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
| Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
| Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
| Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
| Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
| Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |